Impurity A of Calcifediol is a known impurity and degradation product of Calcifediol (25-Hydroxyvitamin D3), which is a key intermediate in the vitamin D metabolic pathway and an active pharmaceutical ingredient (API) used for treating vitamin D deficiency and related bone disorders. This impurity is structurally related to the parent drug and is closely monitored during the pharmaceutical development and manufacturing process of Calcifediol. As a specified impurity, it is critical for quality control and regulatory compliance. It is used as a reference standard in analytical methods, such as high-performance liquid chromatography (HPLC), to identify, quantify, and control its level in the final drug substance and drug products. This ensures the safety, efficacy, and purity of the medicinal product. The characterization and control of this impurity are essential parts of the pharmaceutical quality system, adhering to guidelines from regulatory bodies like the ICH (International Council for Harmonisation). Its availability as a well-characterized standard supports robust stability studies and helps establish appropriate specifications for the API.